Pharma IQ | 06/21/2010
Dr. Mitchell Friedman, Director of Toxicology at Takeda Pharmaceuticals, discusses pre-clinical toxicity and avoiding common mistakes in early development so as to secure patient safety and better ROI.
To continue reading this story Click Here
RECOMMENDED
MSD announces Phase III data on investigational treatment to lower LDL Cholesterol (LDL-C)
2025-11-17
AI for Pharma & Healthcare 2025
2025-06-18
Upcoming Events
Pharma Contract Manufacturing
23 - 25 March 2026
Mercure Hotel MOA Berlin, Germany
Register Now |
View Agenda |
Learn More